At the news
? NEUTRALIMPACT 3/10 144 filed Aug 14, 2026 at 18:56 ET
Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell approximately 82,563 shares of common stock with an estimated aggregate market value of ~$1.9 million. The shares were acquired through restricted stock and performance share grants between 2024 and 2025. This is a relatively small sale relative to C4's $502M market cap, but the insider's role and the timing (no specific catalyst noted) warrant monitoring for potential follow-through sales or insider sentiment shifts.
- Jay L. Geldmacher filed Form 144 to sell up to 82,563 shares of C4 Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is approximately $1,899,926.
- Shares were acquired via restricted stock and performance share grants dated 02/09/2025, 02/14/2025, 02/15/2025, 02/18/2024, and 02/14/2024.
- The filing date is August 14, 2026, with the proposed sale date also listed as August 14, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access